ASFH part 2: CNV and Anti-VEGF Therapy

Subject: part 2 of CNV and Anti-VEGF Therapy Paper Discussed: Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, June 2005, 112(6) p1035-47 Guest: Philip J. Rosenfeld, M.D., Ph.D. Associate Professor of Ophthalmology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida

Episode metadata supplied by the publisher feed · Published May 21, 2010

Embed this episode

Attribution link and audio player

NOW PLAYING

ASFH part 2: CNV and Anti-VEGF Therapy

0:00 25:40

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of As Seen From Here?

This episode is 25 minutes long.

When was this As Seen From Here episode published?

This episode was published on May 21, 2010.

Can I download this As Seen From Here episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!